Trials / Recruiting
RecruitingNCT06959095
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab In Adult Participants With COPD With Type 2 Inflammation
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 981 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Depemokimab | Depemokimab as a sterile liquid formulation will be administered. |
| DRUG | Placebo | Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered. |
Timeline
- Start date
- 2025-06-20
- Primary completion
- 2029-08-20
- Completion
- 2029-08-20
- First posted
- 2025-05-06
- Last updated
- 2025-10-08
Locations
15 sites across 3 countries: United States, China, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06959095. Inclusion in this directory is not an endorsement.